Bicara Therapeutics Inc.’s (NASDAQ:BCAX) Lock-Up Period To End on March 12th

Bicara Therapeutics’ (NASDAQ:BCAX) lock-up period is set to end on Wednesday, March 12th. Bicara Therapeutics had issued 17,500,000 shares in its public offering on September 13th. The total size of the offering was $315,000,000 based on an initial share price of $18.00. After the expiration of Bicara Therapeutics’ lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. HC Wainwright raised their price objective on Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Wedbush reaffirmed an “outperform” rating and issued a $31.00 target price on shares of Bicara Therapeutics in a report on Wednesday, February 12th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $41.20.

Bicara Therapeutics Stock Up 5.1 %

Shares of NASDAQ BCAX opened at $16.55 on Friday. The company has a 50 day moving average price of $13.53. Bicara Therapeutics has a 52-week low of $11.10 and a 52-week high of $28.09.

Institutional Trading of Bicara Therapeutics

A number of large investors have recently modified their holdings of the company. RA Capital Management L.P. purchased a new stake in shares of Bicara Therapeutics in the third quarter valued at approximately $177,169,000. Red Tree Management LLC purchased a new stake in shares of Bicara Therapeutics in the fourth quarter valued at approximately $55,230,000. FMR LLC purchased a new stake in shares of Bicara Therapeutics in the third quarter valued at approximately $57,913,000. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Bicara Therapeutics by 171.9% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,175,265 shares of the company’s stock valued at $37,893,000 after purchasing an additional 1,375,265 shares during the period. Finally, Braidwell LP boosted its holdings in shares of Bicara Therapeutics by 20.7% in the fourth quarter. Braidwell LP now owns 2,000,659 shares of the company’s stock valued at $34,851,000 after purchasing an additional 343,059 shares during the period.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.